US FDA Form 483 at CTO2 facility
The US FDA issued a Form 483 with seven observations at the CTO2 facility in Bollaram, Hyderabad. Management has responded but resolution timeline is uncertain.
DRREDDY / Q3-FY25 / risks
Keep the risk register visible.
Dr. Reddy's Laboratories · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Lenalidomide revenue decline post-2025
Lenalidomide revenue is expected to decline significantly after September-October 2025 as volume restrictions end and competition intensifies.
Iron sucrose approval delay due to CRL
The company received a complete response letter (CRL) on the API side for iron sucrose, delaying the expected launch.
India business underperformance in cardiac and GI segments
Cardiac and gastrointestinal therapy areas are growing slower than the market; management expects recovery but timeline is uncertain.